Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 1
1991 2
1992 2
1993 2
1994 3
1995 9
1996 4
1997 9
1998 8
1999 9
2000 12
2001 9
2002 13
2003 10
2004 14
2005 22
2006 19
2007 23
2008 18
2009 23
2010 26
2011 28
2012 26
2013 31
2014 39
2015 29
2016 15
2017 16
2018 19
2019 35
2020 29
2021 24
2022 19
2023 43
2024 17
2025 28
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

569 results

Results by year

Filters applied: . Clear all
Page 1
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, Lane W, Matos ALSA, Murthy S, Stachlewska K, Rosenstock J. Mathieu C, et al. Lancet. 2023 Jun 10;401(10392):1929-1940. doi: 10.1016/S0140-6736(23)00520-2. Epub 2023 May 5. Lancet. 2023. PMID: 37156252 Clinical Trial.
BACKGROUND: Insulin icodec (icodec) is a basal insulin analogue suitable for once-weekly dosing. ONWARDS 4 aimed to assess the efficacy and safety of once-weekly icodec compared with once-daily insulin glargine U100 (glargine U100) in individuals with long-st …
BACKGROUND: Insulin icodec (icodec) is a basal insulin analogue suitable for once-weekly dosing. ONWARDS 4 aimed to assess the …
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.
Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Heymsfield SB, et al. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457. JAMA Netw Open. 2021. PMID: 33439265 Free PMC article. Clinical Trial.
Previous clinical studies suggest that ActRII inhibition with the monoclonal antibody bimagrumab also promotes excess adipose tissue loss and improves insulin resistance. OBJECTIVE: To evaluate the efficacy and safety of bimagrumab on body composition and glycemic control …
Previous clinical studies suggest that ActRII inhibition with the monoclonal antibody bimagrumab also promotes excess adipose tissue loss an …
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Depommier C, et al. Nat Med. 2019 Jul;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2. Epub 2019 Jul 1. Nat Med. 2019. PMID: 31263284 Free PMC article. Clinical Trial.
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus(1). The gut microbiota is a new key contributor involv …
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardi …
Metabolic Inflammation and Insulin Resistance in Obesity.
Wu H, Ballantyne CM. Wu H, et al. Circ Res. 2020 May 22;126(11):1549-1564. doi: 10.1161/CIRCRESAHA.119.315896. Epub 2020 May 21. Circ Res. 2020. PMID: 32437299 Free PMC article. Review.
Obesity is becoming an epidemic in the United States and worldwide and increases risk for many diseases, particularly insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. The mechanisms linking obesity with these diseases re …
Obesity is becoming an epidemic in the United States and worldwide and increases risk for many diseases, particularly insulin resista …
Skeletal muscle inflammation and insulin resistance in obesity.
Wu H, Ballantyne CM. Wu H, et al. J Clin Invest. 2017 Jan 3;127(1):43-54. doi: 10.1172/JCI88880. Epub 2017 Jan 3. J Clin Invest. 2017. PMID: 28045398 Free PMC article. Review.
Obesity is associated with chronic inflammation, which contributes to insulin resistance and type 2 diabetes mellitus. Under normal conditions, skeletal muscle is responsible for the majority of insulin-stimulated whole-body glucose dispo …
Obesity is associated with chronic inflammation, which contributes to insulin resistance and type 2 diabetes …
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Yanai H, et al. Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942. Int J Mol Sci. 2023. PMID: 37762244 Free PMC article. Review.
The measurement of apo B48, which is a constituent of CM and CMR; non-fasting TG, which includes TG content in all lipoproteins including CM and CMR; non-high-density lipoprotein cholesterol (non-HDL-C), which includes TRLs and low-density lipop …
The measurement of apo B48, which is a constituent of CM and CMR; non-fasting TG, which includes TG content in all lipoprotein …
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C, Allen S, Heine RJ, Lee CJ. Zeitler P, et al. Diabetes Care. 2024 Jun 1;47(6):1056-1064. doi: 10.2337/dc23-2356. Diabetes Care. 2024. PMID: 38639997 Free PMC article. Clinical Trial.
OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide's effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS: This po …
OBJECTIVE: We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPAS …
The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes.
Battelino T, Lalic N, Hussain S, Ceriello A, Klobucar S, Davies SJ, Topsever P, Heverly J, Ulivi F, Brady K, Tankova T, Galhardo J, Tagkalos K, Werson E, Mathieu C, Schwarz P. Battelino T, et al. Diabetes Res Clin Pract. 2025 May;223:112111. doi: 10.1016/j.diabres.2025.112111. Epub 2025 Mar 19. Diabetes Res Clin Pract. 2025. PMID: 40118193 Free article. Review.
However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence th …
However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type …
Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
Jiao R, Lin C, Cai X, Wang J, Wang Y, Lv F, Yang W, Ji L. Jiao R, et al. Diabetes Obes Metab. 2025 Jan;27(1):259-267. doi: 10.1111/dom.16012. Epub 2024 Oct 21. Diabetes Obes Metab. 2025. PMID: 39431379
When compared with controls, substantial reductions in fat body mass were observed in patients using GLP-1 receptor-based agonist treatment (WMD = -2.25 kg, 95% CI -3.40 to -1.10 kg), with decrease in areas of both subcutaneous fat (WMD = -38.35 cm(2), 95% CI, -54.75 to -2 …
When compared with controls, substantial reductions in fat body mass were observed in patients using GLP-1 receptor-based agonist treatment …
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P; EXPECT study group. Mathiesen ER, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):86-95. doi: 10.1016/S2213-8587(22)00307-2. Epub 2023 Jan 6. Lancet Diabetes Endocrinol. 2023. PMID: 36623517 Clinical Trial.
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic profile compared with first-generation basal insulins, but there are few data regarding its use during pregnancy. In this non- …
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic …
569 results